Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 726.39 Billion KRW | 0.58% |
| 2022 | 722.22 Billion KRW | 3.07% |
| 2021 | 700.69 Billion KRW | 1.36% |
| 2020 | 691.32 Billion KRW | 2.97% |
| 2019 | 671.4 Billion KRW | 7.07% |
| 2018 | 627.07 Billion KRW | 68.75% |
| 2017 | 371.59 Billion KRW | -39.8% |
| 2016 | 617.27 Billion KRW | 3.79% |
| 2015 | 594.71 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 173.17 Billion KRW | 1.62% |
| 2024 Q1 | 170.41 Billion KRW | -5.15% |
| 2023 FY | 726.39 Billion KRW | 0.58% |
| 2023 Q3 | 177.2 Billion KRW | -0.71% |
| 2023 Q2 | 178.46 Billion KRW | -6.58% |
| 2023 Q1 | 191.05 Billion KRW | 11.44% |
| 2023 Q4 | 179.66 Billion KRW | 1.39% |
| 2022 Q4 | 171.44 Billion KRW | -2.65% |
| 2022 Q1 | 179.99 Billion KRW | 4.03% |
| 2022 Q2 | 194.67 Billion KRW | 8.15% |
| 2022 FY | 722.22 Billion KRW | 3.07% |
| 2022 Q3 | 176.11 Billion KRW | -9.53% |
| 2021 Q4 | 173.02 Billion KRW | -4.78% |
| 2021 Q2 | 175.5 Billion KRW | 2.96% |
| 2021 Q1 | 170.45 Billion KRW | -1.41% |
| 2021 FY | 700.69 Billion KRW | 1.36% |
| 2021 Q3 | 181.7 Billion KRW | 3.53% |
| 2020 Q3 | 173.25 Billion KRW | -0.62% |
| 2020 Q1 | 170.83 Billion KRW | 2.15% |
| 2020 FY | 691.32 Billion KRW | 2.97% |
| 2020 Q4 | 172.89 Billion KRW | -0.2% |
| 2020 Q2 | 174.33 Billion KRW | 2.05% |
| 2019 FY | 671.4 Billion KRW | 7.07% |
| 2019 Q3 | 166.94 Billion KRW | -2.27% |
| 2019 Q2 | 170.81 Billion KRW | 2.65% |
| 2019 Q1 | 166.39 Billion KRW | 1.18% |
| 2019 Q4 | 167.24 Billion KRW | 0.18% |
| 2018 Q1 | 149.04 Billion KRW | -6.46% |
| 2018 FY | 627.07 Billion KRW | 68.75% |
| 2018 Q4 | 164.46 Billion KRW | 2.66% |
| 2018 Q3 | 160.2 Billion KRW | 4.46% |
| 2018 Q2 | 153.36 Billion KRW | 2.9% |
| 2017 Q2 | 52.96 Billion KRW | 0.0% |
| 2017 Q4 | 159.33 Billion KRW | 0.02% |
| 2017 FY | 371.59 Billion KRW | -39.8% |
| 2017 Q3 | 159.3 Billion KRW | 200.79% |
| 2016 FY | 617.27 Billion KRW | 3.79% |
| 2015 FY | 594.71 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -429.405% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 35.831% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | -13.775% |
| HANDOK Inc. | 522.74 Billion KRW | -38.959% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -436.588% |
| Yuhan Corporation | 1858.98 Billion KRW | 60.925% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | -9.4% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -1298.12% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 51.278% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -438.429% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -96.038% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -719.917% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -328.381% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -223.623% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -429.405% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -830.639% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -380.829% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -731.46% |
| JW Holdings Corporation | 928.07 Billion KRW | 21.731% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | -20.913% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 56.488% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 2.957% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -262.782% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -301.849% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -269.956% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -429.405% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 52.036% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 47.184% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 2.957% |
| Yuhan Corporation | 1858.98 Billion KRW | 60.925% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 8.597% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -209.232% |
| Suheung Co., Ltd. | 594.56 Billion KRW | -22.172% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 2.957% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -148.656% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -160.409% |
| CKD Bio Corp. | 160.35 Billion KRW | -352.997% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | -37.848% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -101.157% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -215.284% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -262.782% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 17.435% |
| Boryung Corporation | 859.62 Billion KRW | 15.499% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -476.831% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -96.038% |
| JW Lifescience Corporation | 206.86 Billion KRW | -251.152% |